Azitra shares surge 10.02% intraday after announcing Biotech Showcase presentation and FDA Fast Track designation for ATR-04.

Azitra surged 10.02% intraday after announcing its participation in the Biotech Showcase 2026 alongside the J.P. Morgan Annual Healthcare Conference. The company highlighted its clinical-stage programs, including ATR-12 for Netherton syndrome and ATR-04 for EGFRi-associated skin toxicity, both leveraging engineered S. epidermidis strains and AI-driven platforms. The Fast Track designation for ATR-04 and the presentation schedule—featuring one-on-one investor meetings—signaled progress in its precision dermatology pipeline. The timing of the news, released on Jan. 7, 2026, ahead of the showcase on Jan. 12–14, likely bolstered investor confidence in its therapeutic innovation and partnership potential.